1.
42nd EASL Coverage --- Coverage of 42nd EASL / Barcelona, Spain The 42nd Annual Meeting of the European Association for the Study of the Liver (42nd EASL) took place April 11 - 15, 2007 in Barcelona, Spain, arguably the ...
2.
Adefovir and Lamivudine Combination Therapy is Superior to ... File Format: Microsoft Powerpoint - View as HTML 42nd EASL, 2007; Barcelona, Spain; Poster #502. Background and aims. Adefovir dipivoxil (ADV) halts the progression of liver disease in lamivudine-resistant ...
3.
FDA Approves New, Less Expensive Female Condom Mar 17, 2009 ... HIVandHepatitis.com: The Internet publication with accurate, timely and cutting-edge information on treatment and vaccines for HIV, ...
4.
Exposure to Hepatitis B Virus May Increase the Risk of Pancreas Cancer Oct 7, 2008 ... Exposure to Hepatitis B Virus May Increase the Risk of Pancreas Cancer ... It is well known that chronic infection with hepatitis B virus ...
5.
Efficacy of 12-month Famciclovir Treatment in Chronic HBeAg ... Feb 18, 2005 ... Famciclovir 500 mg 3 times daily significantly reduced HBV DNA and median HAI scores versus placebo. By week 8, median HBV DNA decreased ...
6.
Preliminary, Top-line Results from Schering Plough's IDEAL Study ... Jan 14, 2008 ... The IDEAL study was undertaken by Schering-Plough as an important step in meeting the needs of the hepatitis C medical and patient ...
7.
HIV and Hepatitis.com - Library of CME/CE Programs 14th CROI -- HIV and Hepatitis Coverage of the 14th CROI Conference.
8.
Raltegravir (isentress)- HIV and Hepatitis.com DOSING. • Raltegravir is an oral drug, and the recommended dose for ... The 400 mg twice-daily raltegravir dose was selected as having the best ...
9.
Excellent Response with a PI- and NRTI-sparing Regimen of ... Raltegravir + Maraviroc Drug Interaction. In a related study presented last month at the 48th International Conference on Antimicrobial Agents and ...
10.
Excellent Response with a PI- and NRTI-sparing Regimen of ... Days 6-11: maraviroc 300 mg q12h; • Days 12-14: raltegravir 400 mg q12h + maraviroc 300 mg q12h. Serial 12 hour pharmacokinetic parameters were assessed on ...
|